Inaro (anagrelide) / Bioprofarma - LARVOL DELTA

HIRA to remove…drugs from Group 2 anticancer list, update reimbursement criteria (Korea Biomedical Review) - "The move, which is aimed at overhauling the reimbursement system and reflecting the latest clinical evidence, will take effect on March 1. The drugs that will be deleted from the list of Group 2 anticancer drugs are albumin-bound paclitaxel, aldesleukin(IL- 2), anagrelide, anastrozole, belotecan, capecitabine..."

Reimbursement • Oncology